Olema Pharmaceuticals (OLMA) Share-based Compensation (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Share-based Compensation data on file, last reported at $10.1 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 131.8% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 70.46% decrease from a year earlier, with the FY2025 full-year figure at $32.1 million, changed N/A from the prior year.
• Share-based Compensation for Q1 2026 stood at $10.1 million, up from -$12.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for OLMA reached as high as $16.9 million in Q4 2023 and fell as low as -$12.4 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $4.2 million in 2025.
• Across the five-year window, Share-based Compensation jumped 15011.61% in 2023 and tumbled 2717.23% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $112000.0 in 2022, then soared by 15011.61% to $16.9 million in 2023, then sank by 102.61% to -$441000.0 in 2024, then tumbled by 2717.23% to -$12.4 million in 2025, then surged by 181.68% to $10.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $10.1 million in Q1 2026, -$12.4 million in Q4 2025, and $4.2 million in Q3 2025.